Literature DB >> 21486929

Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus.

R Silvariño1, F Sant, G Espinosa, G Pons-Estel, M Solé, R Cervera, P Arrizabalaga.   

Abstract

BACKGROUND: Nephropathy associated with antiphospholipid antibodies (aPL) has been proposed as a risk factor of worse renal prognosis in patients with systemic lupus erythematosus (SLE). The purpose of the current study was to evaluate the prevalence of aPL-associated nephropathy (aPLN) among patients with lupus nephritis and to describe their functional renal outcome.
METHODS: A total of 79 renal biopsies from 77 patients followed at the Hospital Clinic, Spain were analysed. Each renal biopsy was evaluated by a pathologist who was blinded to the aPL status. Thrombotic microangiopathy (TMA), fibrous intimal hyperplasia (FIH), fibrocellular arterial occlusion (FAO), focal cortical atrophy (FCA), and tubular thyroidization as lesions suggestive of aPLN were identified.
RESULTS: aPLN was found in nine (11.4%) biopsies. TMA was found in three (33.3%) cases whereas chronic aPLN, represented by FIH and FCA, was found in four (44.4%) and three (33.3%) cases, respectively. A significant association between the presence of aPL and aPLN was found (p = 0.003). Patients with lupus anticoagulant (LA) plus IgG anticardiolipin antibodies (aCL) showed an increased prevalence of aPLN (OR: 3.61, 95% CI 1.28-5.14; p = 0.002). Creatinine levels were significantly increased in patients with aPLN compared with those with aPL without aPLN (p = 0.038). However, no significant difference in complete remission, partial remission, not response, and established renal damage between groups was observed at the end of follow-up.
CONCLUSIONS: The aPL have an important role in the pathogenesis of renal lesions in SLE patients. Prospective studies are needed to address the role of aPLN in the long-term outcome of SLE patients with positive aPL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21486929     DOI: 10.1177/0961203310397410

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  10 in total

Review 1.  Renal involvement in antiphospholipid syndrome.

Authors:  Francisco Vileimar Andrade de Azevedo; Diego Germano Maia; Jozelio Freire de Carvalho; Carlos Ewerton Maia Rodrigues
Journal:  Rheumatol Int       Date:  2018-05-05       Impact factor: 2.631

Review 2.  Renal involvement in antiphospholipid syndrome.

Authors:  Guillermo J Pons-Estel; Ricard Cervera
Journal:  Curr Rheumatol Rep       Date:  2014-02       Impact factor: 4.592

Review 3.  Current treatment of antiphospholipid syndrome: lights and shadows.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Nat Rev Rheumatol       Date:  2015-06-30       Impact factor: 20.543

4.  Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study.

Authors:  Gian Luca Erre; Luisanna Bosincu; Rossana Faedda; Patrizia Fenu; Antonio Masala; Marcella Sanna; Loredana Taras; Maria Giovanna Longu; Marco Piras; Giovanni Soro; Andrea Ercole Satta; Giuseppe Passiu
Journal:  Rheumatol Int       Date:  2014-04       Impact factor: 2.631

5.  The spectrum of renal thrombotic microangiopathy in lupus nephritis.

Authors:  Di Song; Li-hua Wu; Feng-mei Wang; Xiao-wei Yang; Di Zhu; Min Chen; Feng Yu; Gang Liu; Ming-hui Zhao
Journal:  Arthritis Res Ther       Date:  2013-01-15       Impact factor: 5.156

6.  Genome-wide association study of antiphospholipid antibodies.

Authors:  M Ilyas Kamboh; Xingbin Wang; Amy H Kao; Michael M Barmada; Ann Clarke; Rosalind Ramsey-Goldman; Susan Manzi; F Yesim Demirci
Journal:  Autoimmune Dis       Date:  2013-02-24

Review 7.  Renal Involvement in Antiphospholipid Syndrome.

Authors:  Alonso Turrent-Carriles; Juan Pablo Herrera-Félix; Mary-Carmen Amigo
Journal:  Front Immunol       Date:  2018-05-17       Impact factor: 7.561

Review 8.  Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment.

Authors:  Maria G Tektonidou
Journal:  Front Immunol       Date:  2018-05-31       Impact factor: 7.561

9.  The impact of antiphospholipid antibodies in children with lupus nephritis.

Authors:  Sulaiman M Al-Mayouf; Alhanouf AlSaleem; Turki Al-Hussain; Abdullah Al Sonbul; Hadeel AlMana
Journal:  Int J Pediatr Adolesc Med       Date:  2015-11-21

Review 10.  Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations.

Authors:  Myrto Kostopoulou; Antonis Fanouriakis; Kim Cheema; John Boletis; George Bertsias; David Jayne; Dimitrios T Boumpas
Journal:  RMD Open       Date:  2020-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.